These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 21835316)
61. Is a strategy of intended incomplete percutaneous transluminal coronary angioplasty revascularization acceptable in nondiabetic patients who are candidates for coronary artery bypass graft surgery? The Bypass Angioplasty Revascularization Investigation (BARI). Bourassa MG; Kip KE; Jacobs AK; Jones RH; Sopko G; Rosen AD; Sharaf BL; Schwartz L; Chaitman BR; Alderman EL; Holmes DR; Roubin GS; Detre KM; Frye RL J Am Coll Cardiol; 1999 May; 33(6):1627-36. PubMed ID: 10334434 [TBL] [Abstract][Full Text] [Related]
62. Association Between Hemoglobin A1c and Major Adverse Coronary Events in Patients with Diabetes Following Coronary Artery Bypass Surgery. Turgeon RD; Koshman SL; Youngson E; Pearson GJ Pharmacotherapy; 2020 Feb; 40(2):116-124. PubMed ID: 31883378 [TBL] [Abstract][Full Text] [Related]
63. Choice of initial medical therapy vs. prompt coronary revascularization in patients with type 2 diabetes and stable ischemic coronary disease with special emphasis on the BARI 2D trial results. Chaitman BR; Hadid M; Laddu AA Curr Opin Cardiol; 2010 Nov; 25(6):597-602. PubMed ID: 20885315 [TBL] [Abstract][Full Text] [Related]
64. Strategies in stable ischemic heart disease: lessons from the COURAGE and BARI-2D trials. Fernandez SF; Boden WE Curr Atheroscler Rep; 2010 Nov; 12(6):423-31. PubMed ID: 20845088 [TBL] [Abstract][Full Text] [Related]
65. High prevalence and diversity of kidney dysfunction in patients with type 2 diabetes mellitus and coronary artery disease: the BARI 2D baseline data. Wall BM; Hardison RM; Molitch ME; Marroquin OC; McGill JB; August PA; Am J Med Sci; 2010 May; 339(5):401-10. PubMed ID: 20375690 [TBL] [Abstract][Full Text] [Related]
66. Five-year clinical and functional outcome comparing bypass surgery and angioplasty in patients with multivessel coronary disease. A multicenter randomized trial. Writing Group for the Bypass Angioplasty Revascularization Investigation (BARI) Investigators. JAMA; 1997 Mar; 277(9):715-21. PubMed ID: 9042843 [TBL] [Abstract][Full Text] [Related]
67. Peroxisome proliferator-activated receptor pathway gene polymorphism associated with extent of coronary artery disease in patients with type 2 diabetes in the bypass angioplasty revascularization investigation 2 diabetes trial. Cresci S; Wu J; Province MA; Spertus JA; Steffes M; McGill JB; Alderman EL; Brooks MM; Kelsey SF; Frye RL; Bach RG; Circulation; 2011 Sep; 124(13):1426-34. PubMed ID: 21911782 [TBL] [Abstract][Full Text] [Related]
68. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation; 1997 Sep; 96(6):1761-9. PubMed ID: 9323059 [TBL] [Abstract][Full Text] [Related]
69. Predictors of mortality and mortality from cardiac causes in the bypass angioplasty revascularization investigation (BARI) randomized trial and registry. For the BARI Investigators. Brooks MM; Jones RH; Bach RG; Chaitman BR; Kern MJ; Orszulak TA; Follmann D; Sopko G; Blackstone EH; Califf RM Circulation; 2000 Jun; 101(23):2682-9. PubMed ID: 10851204 [TBL] [Abstract][Full Text] [Related]
70. Outcomes of noncardiac surgery after coronary bypass surgery or coronary angioplasty in the Bypass Angioplasty Revascularization Investigation (BARI). Hassan SA; Hlatky MA; Boothroyd DB; Winston C; Mark DB; Brooks MM; Eagle KA Am J Med; 2001 Mar; 110(4):260-6. PubMed ID: 11239843 [TBL] [Abstract][Full Text] [Related]
71. Body mass index and health status in the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial (BARI 2D). Chung SC; Hlatky MA; Stone RA; Rana JS; Escobedo J; Rogers WJ; Bromberger JT; Kelsey SF; Brooks MM Am Heart J; 2011 Jul; 162(1):184-92.e3. PubMed ID: 21742107 [TBL] [Abstract][Full Text] [Related]